- Home
- GPCR vs GYRE Comparison
GPCR vs GYRE Comparison
Compare GPCR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- GYRE
- Stock Information
- Founded
- GPCR 2016
- GYRE 2002
- Country
- GPCR United States
- GYRE United States
- Employees
- GPCR N/A
- GYRE N/A
- Industry
- GPCR
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- GPCR
- GYRE Health Care
- Exchange
- GPCR Nasdaq
- GYRE Nasdaq
- Market Cap
- GPCR 1.1B
- GYRE 897.1M
- IPO Year
- GPCR 2023
- GYRE N/A
- Fundamental
- Price
- GPCR $23.82
- GYRE $10.39
- Analyst Decision
- GPCR Strong Buy
- GYRE
- Analyst Count
- GPCR 9
- GYRE 0
- Target Price
- GPCR $77.50
- GYRE N/A
- AVG Volume (30 Days)
- GPCR 1.1M
- GYRE 112.1K
- Earning Date
- GPCR 05-08-2025
- GYRE 05-09-2025
- Dividend Yield
- GPCR N/A
- GYRE N/A
- EPS Growth
- GPCR N/A
- GYRE N/A
- EPS
- GPCR N/A
- GYRE 0.02
- Revenue
- GPCR N/A
- GYRE $100,643,000.00
- Revenue This Year
- GPCR N/A
- GYRE $22.01
- Revenue Next Year
- GPCR N/A
- GYRE $88.14
- P/E Ratio
- GPCR N/A
- GYRE $127.70
- Revenue Growth
- GPCR N/A
- GYRE N/A
- 52 Week Low
- GPCR $13.22
- GYRE $6.11
- 52 Week High
- GPCR $62.74
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- GPCR 51.16
- GYRE 57.93
- Support Level
- GPCR $25.06
- GYRE $8.51
- Resistance Level
- GPCR $27.50
- GYRE $11.78
- Average True Range (ATR)
- GPCR 1.86
- GYRE 0.74
- MACD
- GPCR -0.31
- GYRE 0.23
- Stochastic Oscillator
- GPCR 28.77
- GYRE 58.75
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.